Atlas Trials

RET-altered Papillary Thyroid Cancer

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch RET-altered Papillary Thyroid Cancer

RecordFirmDate
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385)Hoffmann-La Roche2017-03-17

Track RET-altered Papillary Thyroid Cancer automatically

Every clearance here is in the API, with alerts when new ones post.